Cosmos Health Signs Three-Year Manufacturing Contract
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Source: NASDAQ.COM
- Contract Signing: Cosmos Health's subsidiary, Cana Laboratories, has signed a three-year manufacturing contract with Verisfield Pharmaceuticals SA, expected to produce 3.9 million VASCLOR GEST 400 mg vaginal pessaries for assisted reproduction, marking the company's expansion into women's health.
- Market Impact: Despite securing this significant contract, Cosmos Health's shares fell over 10% on Thursday, currently trading at $0.20, indicating market concerns regarding the company's future profitability.
- Product Supply: Under the agreement, Cana is set to manufacture 1.3 million VASCLOR GEST pessaries, packaged in boxes of 15 units, to meet the European market demand for assisted reproduction products, thereby enhancing the company's competitive position.
- Compliance Upgrade: Cana is upgrading its facilities in accordance with Good Manufacturing Practices (GMP) protocols to ensure product quality meets international standards, thereby boosting its credibility and customer trust in the European market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Reports Record Q2 Revenue Exceeding $15 Million
- Significant Revenue Growth: CosmoFarm reported over $15 million in revenue for Q2 2026, translating to an annualized run-rate exceeding $60 million, indicating strong growth potential in the pharmaceutical wholesale market in the greater Athens area.
- Accelerated Network Expansion: The addition of over 80 new pharmacies during this period further solidifies CosmoFarm's market position and enhances the trust of its growing customer base in its distribution platform.
- Increased Capital Expenditure: To support ongoing growth, Cosmos Health is ramping up capital expenditures at CosmoFarm, investing in new robotic automation and AI systems to enhance efficiency in procurement, inventory management, and order fulfillment.
- Facility Expansion Plans: The company is also planning to expand the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion, aiming to improve margins and achieve sustainable profit growth.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Cosmos Health Enters Global Beauty and Personal Care Market
- Market Expansion: Cosmos Health officially enters the global beauty and personal care market with the launch of a premium collagen-based skincare brand, which has been on sale in the U.S. for over a month, marking a strategic move into the high-growth skincare category.
- Innovative Sales Model: The brand utilizes a direct-to-consumer sales model aimed at global expansion, and it is expected to enhance the company's product portfolio through a multi-brand strategy, thereby increasing market competitiveness.
- Significant Market Potential: According to Grand View Research, the global skincare market was valued at approximately $163 billion in 2026 and is projected to reach $203 billion by 2033, indicating rapid growth potential for premium skincare products driven by consumer demand for science-backed formulations.
- Strategic Importance: CEO Greg Siokas stated that entering the beauty market is a natural extension of the company's diversification strategy, and this new venture is expected to become a significant growth driver, contributing to higher profit margins and market share.
See More
Cosmos Health Signs Five-Year Manufacturing Agreement with Pharmex
- Manufacturing Agreement: Cosmos Health has entered a five-year contract manufacturing agreement with Pharmex S.A., indicating the company's intent to expand its footprint in the pharmaceutical sector through its subsidiary Cana Laboratories.
- Production Capacity Enhancement: The total output over five years is expected to reach 2.86 million units, including 450,000 units annually of BETAFUSIN cream, 65,000 units of BOTAFEX solution, and 57,000 units of BUDESODERM cream, significantly improving the company's manufacturing capabilities and facility utilization.
- Positive Market Reaction: Following the announcement of this agreement, COSM's stock rose by 7.72%, currently trading at $0.27, reflecting market optimism regarding the company's future growth potential.
- Strategic Implications: This agreement not only strengthens Cosmos Health's manufacturing capabilities but also lays the groundwork for future product expansion and market share growth, further solidifying its position in the pharmaceutical industry.
See More
Cosmos Health Signs Five-Year Manufacturing Agreement with Pharmex
- Contract Manufacturing Agreement: Cosmos Health has signed a five-year contract manufacturing agreement with Pharmex through its subsidiary Cana Laboratories, expected to produce approximately 2.86 million units of three pharmaceutical products over the term, reinforcing its position in the contract manufacturing sector.
- Production Details: Under the agreement, Cana will manufacture BETAFUSIN®, BOTAFEX®, and BUDESODERM® at its EU-GMP-licensed facility, with annual production of 450,000 units for BETAFUSIN® alone, totaling 2.25 million units over five years, indicating strong market demand.
- Increased Capacity Utilization: This agreement not only enhances the utilization of Cana's production capacity but also brings higher contract manufacturing revenues to Cosmos Health, which is expected to strengthen the company's long-term financial stability and profitability.
- Strategic Partnership Outlook: CEO Greg Siokas stated that this collaboration reflects the strength of their manufacturing platform, and the company aims to expand its partnership with Pharmex over time, enhancing its competitive edge in the market.
See More
Cosmos Health Secures New Contract Manufacturing Orders
- Contract Manufacturing Orders: Cosmos Health's wholly-owned subsidiary, Cana Laboratories, has secured new contract manufacturing orders from Nassington and Verisfield for a total of 253,657 units, reflecting strong demand for its contract manufacturing capabilities.
- Product Diversity: The orders encompass a range of pharmaceuticals, including Gritse oral solutions and Fungofort spray, indicating Cana's extensive product portfolio in the pharmaceutical sector, which enhances its market competitiveness.
- Strategic Partnership Deepening: By strengthening relationships with established pharmaceutical partners, Cana solidifies its position in a diversified manufacturing business, thereby creating long-term value for shareholders.
- Global Expansion Plans: Cosmos Health is expanding its operations across Europe, Asia, and North America through its subsidiaries, while also focusing on R&D partnerships to address major health issues, showcasing its ambition for a global strategy.
See More
Cosmos Health Reports Record Q2 Revenue Exceeding $15 Million
- Significant Revenue Growth: CosmoFarm reported over $15 million in revenue for Q2 2026, translating to an annualized run-rate exceeding $60 million, indicating strong growth potential in the pharmaceutical wholesale market in the greater Athens area.
- Accelerated Network Expansion: The addition of over 80 new pharmacies during this period further solidifies CosmoFarm's market position and enhances the trust of its growing customer base in its distribution platform.
- Increased Capital Expenditure: To support ongoing growth, Cosmos Health is ramping up capital expenditures at CosmoFarm, investing in new robotic automation and AI systems to enhance efficiency in procurement, inventory management, and order fulfillment.
- Facility Expansion Plans: The company is also planning to expand the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion, aiming to improve margins and achieve sustainable profit growth.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Cosmos Health Enters Global Beauty and Personal Care Market
- Market Expansion: Cosmos Health officially enters the global beauty and personal care market with the launch of a premium collagen-based skincare brand, which has been on sale in the U.S. for over a month, marking a strategic move into the high-growth skincare category.
- Innovative Sales Model: The brand utilizes a direct-to-consumer sales model aimed at global expansion, and it is expected to enhance the company's product portfolio through a multi-brand strategy, thereby increasing market competitiveness.
- Significant Market Potential: According to Grand View Research, the global skincare market was valued at approximately $163 billion in 2026 and is projected to reach $203 billion by 2033, indicating rapid growth potential for premium skincare products driven by consumer demand for science-backed formulations.
- Strategic Importance: CEO Greg Siokas stated that entering the beauty market is a natural extension of the company's diversification strategy, and this new venture is expected to become a significant growth driver, contributing to higher profit margins and market share.
See More
Cosmos Health Signs Five-Year Manufacturing Agreement with Pharmex
- Manufacturing Agreement: Cosmos Health has entered a five-year contract manufacturing agreement with Pharmex S.A., indicating the company's intent to expand its footprint in the pharmaceutical sector through its subsidiary Cana Laboratories.
- Production Capacity Enhancement: The total output over five years is expected to reach 2.86 million units, including 450,000 units annually of BETAFUSIN cream, 65,000 units of BOTAFEX solution, and 57,000 units of BUDESODERM cream, significantly improving the company's manufacturing capabilities and facility utilization.
- Positive Market Reaction: Following the announcement of this agreement, COSM's stock rose by 7.72%, currently trading at $0.27, reflecting market optimism regarding the company's future growth potential.
- Strategic Implications: This agreement not only strengthens Cosmos Health's manufacturing capabilities but also lays the groundwork for future product expansion and market share growth, further solidifying its position in the pharmaceutical industry.
See More
Cosmos Health Signs Five-Year Manufacturing Agreement with Pharmex
- Contract Manufacturing Agreement: Cosmos Health has signed a five-year contract manufacturing agreement with Pharmex through its subsidiary Cana Laboratories, expected to produce approximately 2.86 million units of three pharmaceutical products over the term, reinforcing its position in the contract manufacturing sector.
- Production Details: Under the agreement, Cana will manufacture BETAFUSIN®, BOTAFEX®, and BUDESODERM® at its EU-GMP-licensed facility, with annual production of 450,000 units for BETAFUSIN® alone, totaling 2.25 million units over five years, indicating strong market demand.
- Increased Capacity Utilization: This agreement not only enhances the utilization of Cana's production capacity but also brings higher contract manufacturing revenues to Cosmos Health, which is expected to strengthen the company's long-term financial stability and profitability.
- Strategic Partnership Outlook: CEO Greg Siokas stated that this collaboration reflects the strength of their manufacturing platform, and the company aims to expand its partnership with Pharmex over time, enhancing its competitive edge in the market.
See More
Cosmos Health Secures New Contract Manufacturing Orders
- Contract Manufacturing Orders: Cosmos Health's wholly-owned subsidiary, Cana Laboratories, has secured new contract manufacturing orders from Nassington and Verisfield for a total of 253,657 units, reflecting strong demand for its contract manufacturing capabilities.
- Product Diversity: The orders encompass a range of pharmaceuticals, including Gritse oral solutions and Fungofort spray, indicating Cana's extensive product portfolio in the pharmaceutical sector, which enhances its market competitiveness.
- Strategic Partnership Deepening: By strengthening relationships with established pharmaceutical partners, Cana solidifies its position in a diversified manufacturing business, thereby creating long-term value for shareholders.
- Global Expansion Plans: Cosmos Health is expanding its operations across Europe, Asia, and North America through its subsidiaries, while also focusing on R&D partnerships to address major health issues, showcasing its ambition for a global strategy.
See More
